Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Nintedanib (Vargatef) for metastatic colorectal cancer – second and subsequent line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions Colorectal cancer is the fourth most common cancer in the UK and starts in either the large bowel (colon) or back passage (rectum). Metastatic colorectal cancer is cancer that has spread to another part of the body, this is most commonly to the liver. Over half of patients with colorectal cancer will eventually develop metastatic disease after their first treatment for colorectal cancer.
Ninedanib is a new drug for the treatment of colorectal cancer given as a tablet twice a day. Some studies have suggested nintedanib may be helpful for patients whose first treatment has failed and whose disease has spread and become metastatic.
If nintedanib is licensed for use in the UK, it could be a new treatment option for patients with metastatic colorectal cancer. This may improve survival and the quality of life of patients when current treatments have stopped working. Indexing Status Subject indexing assigned by CRD MeSH Colorectal Neoplasms; Humans; Indoles Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000517 Date abstract record published 15/03/2016 |